Eligibility Determination
Patient with Preexisting Immunity to AAV Vectors Granted Gene Therapy After Antibody-Depleting Agent Allowed Eligibility
gene therapy; AAV antibodies; ineligible; antibody-chopping drug; clinical trial; eligibility
FDA Institutes Stricter, Targeted COVID Vaccine Policy, Moving Away from ‘One-Size-Fits-All’ Approach
FDA; COVID-19; vaccine policy; vaccine eligibility; clinical trials; high-risk groups; elderly; policy change; public health